An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan

SHANG-GIN WUChiang, Chi-LuChi-LuChiangLiu, Chien-YingChien-YingLiuWang, Chin-ChouChin-ChouWangSu, Po-LanPo-LanSuHsia, Te-ChunTe-ChunHsiaJIN-YUAN SHIHChang, Gee-ChenGee-ChenChang2021-05-022021-05-0220202234-943Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85091211536&doi=10.3389%2ffonc.2020.01481&partnerID=40&md5=d1822ee1e04610fca9fdda688d90c8e9https://scholars.lib.ntu.edu.tw/handle/123456789/558531[SDGs]SDG3afatinib; epidermal growth factor receptor; erlotinib; gefitinib; osimertinib; adult; aged; Article; body fluid; bone metastasis; disease exacerbation; EGFR T790M mutation; female; gene mutation; human; human tissue; limit of detection; liver metastasis; lung adenocarcinoma; lung tumor; lymph node metastasis; male; needle biopsy; observational study; overall survival; retrospective study; smoking; thorax radiography; treatment duration; tumor recurrenceAn Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwanjournal article10.3389/fonc.2020.014812-s2.0-85091211536